IF a protein language model (PLM)-guided, activity-enhanced GLO1 variant — engineered using PLM-identified substitutions that improve catalytic efficiency without altering cofactor selectivity (zinc/GSH), and delivered as lipid nanoparticle (LNP)-encapsulated modified mRNA, targeting liver and vascular endothelium — is administered to 18-month-old male and female C57BL/6J mice via repeated intravenous injection (weekly for 8 weeks),

THEN a measurable reduction (≥30%) in tissue methylglyoxal (MG) levels, MG-derived hydroimidazolone-1 (MG-H1) adducts, and Nε-carboxyethyl-lysine (CEL) AGEs will be detected in aortic and hepatic tissue, accompanied by improved vascular compliance (pulse wave velocity) and reduced plasma dicarbonyl stress markers,

BECAUSE the following causal chain operates:

1. PLMs can systematically identify amino acid substitutions that enhance enzyme catalytic activity — demonstrated for Uracil-N-glycosylase (UNG), where PLM-guided substitutions dramatically reduced the experimental screening burden while yielding verified activity-enhancing variants (PLM-assisted enzyme engineering reduces burden of identifying activity-enhancing substitutions)[https://doi.org/10.1101/2023.10.29.564583]; the same computational framework is substrate-agnostic and applicable to any enzyme whose sequence is embedded in PLM training corpora, including GLO1 (UniProt P78375).

2. Aging tissues accumulate methylglyoxal as a consequence of declining GLO1 activity — this accumulated reactive dicarbonyl pool constitutes a form of chemical damage distinct from stable AGE crosslinks; circulating and tissue MG concentrations rise with age and drive ongoing formation of MG-H1 and CEL modifications on long-lived proteins including collagen, elastin, and myelin (Research Context — GLO1 activator rationale).

3. The GLO1 small-molecule activator space is entirely unexplored as a direct enzyme-binding modality — virtually all existing GLO1 chemistry targets inhibition for oncology applications, and the only documented activity-enhancing intervention (tRES-HESP) operates transcriptionally via Nrf2 upregulation rather than through direct protein binding or intrinsic catalytic enhancement (Research Context — activator chemical space is virgin).

4. A PLM-engineered hyperactive GLO1 variant, delivered as mRNA, would transiently but repeatedly elevate GLO1 activity in tissues where MG accumulates — LNP-mRNA platforms achieve hepatic and endothelial transfection at clinically validated efficiencies; repeated dosing maintains protein expression without genomic integration risk [SPECULATIVE — no direct citation in Evidence Set for GLO1 mRNA delivery specifically].

5. Degradation of the accumulated MG pool by hyperactive GLO1 removes the substrate for ongoing MG-H1/CEL formation — while stable crosslinks already formed are not directly broken, depletion of reactive MG constitutes repair/degradation of the accumulated reactive damage species itself; ...

SENS category: GlycoSENS

Key references: • doi.org/10.1101/2023.10.29.564583]; • doi.org/10.1101/2023.10.29.564583].